Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307252015> ?p ?o ?g. }
- W4307252015 endingPage "237" @default.
- W4307252015 startingPage "227" @default.
- W4307252015 abstract "Congenital hemophilia B is a rare bleeding disorder caused by defects in the gene encoding factor IX (FIX) leading to coagulation deficiency. Recurrent bleeds may cause chronic pain, disability, and reduced quality of life. Phase 2 b and 3 single-arm, open-label, single-dose trials assessing etranacogene dezaparvovec gene therapy for hemophilia B have demonstrated sustained FIX activity levels over observed periods, but long-term durability of the treatment effect has not been established. Using statistical modeling, we estimate long-term durability of FIX activity levels after receiving etranacogene dezaparvovec.Participants from Phase 2 b (N = 3; NCT03489291) and 3 studies (N = 52; NCT03569891) were included. Two participants who did not respond to treatment were excluded. FIX activity was assessed by one-stage activated partial thromboplastin time assay. FIX activity levels at Month 6 post-treatment were considered baseline. Bayesian and Frequentist linear mixed models predicted FIX activity levels up to 25.5 years at an individual and population level with pre-treatment adeno-associated virus 5 (AAV5) neutralizing antibody (NAb) status as primary covariate.Bayesian and Frequentist linear mixed models predicted no more than 6/55 (10.91%) observed participants would have FIX activity levels <2% up to 25.5 years post-infusion. Bayesian model-based predictions of future participants suggest >80% would be free from prophylactic FIX replacement products 25.5 years post-infusion. Both models predicted FIX activity levels were not significantly influenced by pre-treatment AAV5 NAb status.People with hemophilia B receiving etranacogene dezaparvovec would likely achieve durable FIX activity levels and remain free of prophylactic FIX replacement products for up to 25.5 years following single administration. The long-term factor IX durability predictions are based on statistical methods and results in vivo may differ.Hemophilia B is a rare bleeding condition where blood does not clot properly, causing excessive bleeding. It is caused by a change or mutation to a gene, leading to lower-than-normal levels of a clotting factor, called factor IX. Standard treatment involves replacing missing factor IX through lifelong, regular treatment with factor replacement products. Etranacogene dezaparvovec is a gene therapy developed to replace the faulty gene and increase factor IX activity levels in the blood, thereby reducing bleeding, after one treatment. In clinical trials of etranacogene dezaparvovec, people with severe or moderately severe hemophilia B had stable and long-lasting increases in factor IX activity levels that reached near to the normal range seen in people without hemophilia B.The purpose of this study was to predict whether these increases in factor IX activity levels will last over an extended period of time after receiving etranacogene dezaparvovec.Mathematical predictions showed less than 11% of clinical trial participants would have unacceptable factor IX activity levels (less than 2%) up to 25.5 years after receiving etranacogene dezaparvovec. Further predictions of potential future people with hemophilia B showed that over 80% would not need treatment with factor replacement products 25.5 years after receiving etranacogene dezaparvovec.The goal of treatment is to increase factor IX activity levels into the near-to-normal range in people with hemophilia B and therefore decrease or eliminate bleeding. These results suggest people with hemophilia B receiving etranacogene dezaparvovec would have long-lasting factor IX activity levels and would not need regular factor replacement products for up to 25.5 years following a single treatment of etranacogene dezaparvovec." @default.
- W4307252015 created "2022-10-30" @default.
- W4307252015 creator A5001151898 @default.
- W4307252015 creator A5005493549 @default.
- W4307252015 creator A5021544441 @default.
- W4307252015 creator A5049907816 @default.
- W4307252015 creator A5053864014 @default.
- W4307252015 date "2022-10-25" @default.
- W4307252015 modified "2023-10-18" @default.
- W4307252015 title "Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B" @default.
- W4307252015 cites W1969271703 @default.
- W4307252015 cites W1976329054 @default.
- W4307252015 cites W1992365936 @default.
- W4307252015 cites W2035583871 @default.
- W4307252015 cites W2046585038 @default.
- W4307252015 cites W2124762750 @default.
- W4307252015 cites W2323528857 @default.
- W4307252015 cites W2557461095 @default.
- W4307252015 cites W2605719240 @default.
- W4307252015 cites W2767505578 @default.
- W4307252015 cites W2773253161 @default.
- W4307252015 cites W2773565340 @default.
- W4307252015 cites W2774511679 @default.
- W4307252015 cites W2790197520 @default.
- W4307252015 cites W2951513309 @default.
- W4307252015 cites W2972588675 @default.
- W4307252015 cites W2982694372 @default.
- W4307252015 cites W2988055556 @default.
- W4307252015 cites W3047046471 @default.
- W4307252015 cites W3093323554 @default.
- W4307252015 cites W3129688332 @default.
- W4307252015 cites W3171241404 @default.
- W4307252015 cites W3189383694 @default.
- W4307252015 cites W3211760408 @default.
- W4307252015 cites W3211832397 @default.
- W4307252015 cites W3212305051 @default.
- W4307252015 cites W3213236708 @default.
- W4307252015 cites W4210258865 @default.
- W4307252015 cites W4221076899 @default.
- W4307252015 cites W4226054387 @default.
- W4307252015 cites W4226255158 @default.
- W4307252015 cites W4232780230 @default.
- W4307252015 cites W4252214369 @default.
- W4307252015 cites W4285992907 @default.
- W4307252015 cites W4379377935 @default.
- W4307252015 doi "https://doi.org/10.1080/03007995.2022.2133492" @default.
- W4307252015 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36285399" @default.
- W4307252015 hasPublicationYear "2022" @default.
- W4307252015 type Work @default.
- W4307252015 citedByCount "7" @default.
- W4307252015 countsByYear W43072520152023 @default.
- W4307252015 crossrefType "journal-article" @default.
- W4307252015 hasAuthorship W4307252015A5001151898 @default.
- W4307252015 hasAuthorship W4307252015A5005493549 @default.
- W4307252015 hasAuthorship W4307252015A5021544441 @default.
- W4307252015 hasAuthorship W4307252015A5049907816 @default.
- W4307252015 hasAuthorship W4307252015A5053864014 @default.
- W4307252015 hasBestOaLocation W43072520151 @default.
- W4307252015 hasConcept C105795698 @default.
- W4307252015 hasConcept C107673813 @default.
- W4307252015 hasConcept C126322002 @default.
- W4307252015 hasConcept C159110408 @default.
- W4307252015 hasConcept C160234255 @default.
- W4307252015 hasConcept C162376815 @default.
- W4307252015 hasConcept C187212893 @default.
- W4307252015 hasConcept C2778261982 @default.
- W4307252015 hasConcept C2778382381 @default.
- W4307252015 hasConcept C2779951463 @default.
- W4307252015 hasConcept C2781221834 @default.
- W4307252015 hasConcept C2908647359 @default.
- W4307252015 hasConcept C33923547 @default.
- W4307252015 hasConcept C71924100 @default.
- W4307252015 hasConcept C99454951 @default.
- W4307252015 hasConceptScore W4307252015C105795698 @default.
- W4307252015 hasConceptScore W4307252015C107673813 @default.
- W4307252015 hasConceptScore W4307252015C126322002 @default.
- W4307252015 hasConceptScore W4307252015C159110408 @default.
- W4307252015 hasConceptScore W4307252015C160234255 @default.
- W4307252015 hasConceptScore W4307252015C162376815 @default.
- W4307252015 hasConceptScore W4307252015C187212893 @default.
- W4307252015 hasConceptScore W4307252015C2778261982 @default.
- W4307252015 hasConceptScore W4307252015C2778382381 @default.
- W4307252015 hasConceptScore W4307252015C2779951463 @default.
- W4307252015 hasConceptScore W4307252015C2781221834 @default.
- W4307252015 hasConceptScore W4307252015C2908647359 @default.
- W4307252015 hasConceptScore W4307252015C33923547 @default.
- W4307252015 hasConceptScore W4307252015C71924100 @default.
- W4307252015 hasConceptScore W4307252015C99454951 @default.
- W4307252015 hasIssue "2" @default.
- W4307252015 hasLocation W43072520151 @default.
- W4307252015 hasLocation W43072520152 @default.
- W4307252015 hasOpenAccess W4307252015 @default.
- W4307252015 hasPrimaryLocation W43072520151 @default.
- W4307252015 hasRelatedWork W177906890 @default.
- W4307252015 hasRelatedWork W1996901858 @default.
- W4307252015 hasRelatedWork W2024491237 @default.
- W4307252015 hasRelatedWork W2422626978 @default.
- W4307252015 hasRelatedWork W2512946282 @default.